# Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients

> **NCT01047553** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 251 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Formoterol (OT)

## Key facts

- **NCT ID:** NCT01047553
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2011-01
- **Final completion:** 2011-07
- **Target enrollment:** 251 (ACTUAL)
- **Last updated:** 2013-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01047553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01047553, "Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01047553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*